Menu Schließen

CKD & Burden of Disease

CKD & Burden of Disease

Chronic kidney disease (CKD) is a major global disease burden and leads to substantial worldwide morbidity and mortality. An estimated 5–10 million people die annually from kidney disease1.
Due to the constant rise of risk factors of CKD, such as diabetes, obesity and hypertension, the prevalence of CKD is also increasing: the estimated number of disability-adjusted life years attributable to kidney disease globally increased from 19 million in 1990 to 33 million in 20132. CKD mostly develops over years and often progresses to end-stage renal disease (ESRD), requiring costly renal replacement therapy in the form of dialysis or transplantation.

1 https://www.who.int/bulletin/volumes/ 96/6/17-206441.pdf
2 https://www.thelancet.com/journals/lancet /article/PIIS0140-6736(15)61340-X/fulltext

Current and projected prevalence of kidney failure requiring kidney replacement therapy

Growth is continuously outpacing the capacity of kidney replacement therapy (KRT), defined as maintenance dialysis or kidney transplant, especially in low-income and middle-income countries.

  1. National prevalence of peritoneal dialysis (# of patients).
  2. Estimated worldwide need and projected capacity for KRT by 2030. pmp, per million population.
    Adapted with permission from the ISN Global Kidney Health Atlas 2019

Sources:

  1. USRDS 2020 ESRD Report, Tang 2020 Dialysis in Asia, Chen 2020 Kidney tx in China, anzdata 2020, Zakharova 2018 Kidney Tx in Russia,
  2. Himmelfarb et al., ‘The current and future landscape of dialysis’, Nature Reviews, July 2020

Stefan Wohlfeil

Board Member
Stefan Wohlfeil, MD, has over 35 years of experience in the Pharma and Biotech industry. Most recently he was Chief Medical Officer and Head of R&D at Vifor Pharma with responsibility for preclinical and clinical R&D, regulatory and medical affairs as well as drug safety. Prior to that he was Global Head Clinical Research & Pharmacology at Novartis and Bayer. He also has experience as founder and CEO of two start-up companies in the oncology area, one of which was based in Japan. Stefan started his career at Bayer Pharma, where he worked for over 20 years in discovery research and preclinical and clinical development in Germany, USA and Japan. Stefan holds a Medical Doctor’s degree from the University of Düsseldorf, Germany.

Andreas Schmidt

CFO / Board

Andreas Schmid has more than 25 years of experience in Finance in the Life Sciences. He worked as a Pharma Analyst at Merrill Lynch and also has experience in fund raising as well as business development.

During the span of his career Andreas was one of the highest-ranked dialysis and generic pharma analysts, with special expertise in European and CEE/emerging markets. His coverage universe included companies such as Fresenius/FMC (Germany), Gambro (Sweden), Stada (Germany) and Aspen (South Africa). Furthermore, he played a major part in the IPOs of Zentiva (Czech Republic) and Hikma (Jordan). Andreas has also been active as a speaker at various industry conferences, for example in New York, Frankfurt, but also in Warsaw and other Eastern European countries.

In addition, Andreas works as finance lecturer at the Hochschule Pforzheim and is a board member of the German shareholder association SdK.

Ricardo Cordero

Vice Chairman
Dr Ricardo Cordero, PhD, serves as Vice Chairman of Opterion Health since 2016. Ricardo has over 30 years of experience in the Financial Services Industry where he held various senior positions, for example as CEO of BZ Bank, Managing Partner at Reichmuth & Co Investmentfonds AG, Co-founder and Co-CEO at BWO Bank, etc. Further, he is a passionate and experienced private Swiss investor and holds various investments in the Life Science, Technology and high-end Consumer Goods industry.

David Ebsworth

Chairman
Dr David Ebsworth, PhD, has been Chairman of Opterion Health since December 2016. David has over 40 years of experience in the Pharma, Healthcare and Biotech industry. David is a past CEO of Galenica, Vifor Pharma as well as Oxford GlycoSciences and past global head of the Pharmaceutical Division of Bayer. He has chaired several private and public companies and has served on numerous boards as either chairman of the audit, remuneration or nominations and governance committees. David is currently Chairman of Verona Pharma and Actimed Therapeutics.

Guido Grentzmann

CEO / CSO / Board
Dr Guido Grenzmann, PhD, is the founder of Opterion Health and has more than 25 years of experience in Pharma R&D and Project Management. After academic work on bacterial and viral mechanisms of translational regulation, he became Group Leader Molecular Biology/Genomics at Pfizer and Director Biochemistry/GeneProfiling at Altana Pharma where he worked in Discovery of inflammation in respiratory diseases. In 2007 he founded PBS PharmaBioServices providing contract research and consulting mainly in inflammatory diseases, in multiple therapeutic domains. 2012, Guido founded Opterion, with the aim to develop a new PD solution, to decrease side-effects of this promising therapy.